Democratic senators Angela Alsobrooks and Ron Wyden have asked the Department of Health and Human Services (HHS) what safeguards surround prediction markets tied to clinical trial outcomes and Food and Drug Administration approvals. Their inquiry focuses on Kalshi, which launched a pilot program in July 2026 allowing users to bet on late-stage clinical trial endpoints and FDA decisions. No trading volumes have been reported for these contracts, and HHS has not publicly responded. Researchers from Boston University and other institutions warned that market odds could affect trial integrity, treatment adherence among participants and public confidence, particularly concerning vaccines. Public Citizen called betting on clinical trial outcomes its “Outrage of the Month” on November 2, 2026.
Source: Read the original article
